All In MedTech

Device Trial Radar · NCT05301335

Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

Spinal Cord Neuromodulator by SpineX and Scone to Treat Neurogenic Bladder

Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

May 25, 2022

Primary completion

May 1, 2024

Study completion May 1, 2024

Sponsor

Lead sponsor
SpineX Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Rancho Los Amigos National Rehabilitation Center, Downey, California, United States; Atrium Health, Charlotte, North Carolina, United States; MedStar National Rehabilitation Network, Washington, District of Columbia, United States; University of California, San Diego; Craig Hospital, Englewood, Colorado, United States; Columbia University; Institute of Brain and Spine (IBS Hospital), New Delhi, India; International Collaboration On Repair Discoveries (ICORD), Vancouver, British Columbia, Canada; University of Miami, Miami, United States; Mayo Clinic, Rochester, Minnesota, United States; Shepherd Center, Atlanta GA; Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States
First posted
Mar 29, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction

Conditions

  • Neurogenic Bladder
  • Spinal Cord Injuries (Complete and Incomplete)
  • Stroke
  • Multiple Sclerosis

Interventions

  • SCONEDevice

    The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neurogenic Bladder Symptom Score (NBSS)Time frame: 12 weeks

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Rancho Research Institute

    Downey, California

  • UC San Diego Health Systems

    San Diego, California

  • Craig Hospital

    Denver, Colorado

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.